Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Year-End Rush Of NDA Submissions Missing In 2004, But Approvals Are Up

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA received eight applications in December, down from 17 in the last month of 2003. However, 2004 marked a return to the agency’s historical flood of year-end approvals.

You may also be interested in...



Cephalon Will Add 250-Rep Pediatric Sales Force For Modafinil ADHD Launch

The firm plans two launches for early 2006: modafinil for attention deficit/hyperactivity disorder (formerly under the trade name Attenace) and Nuvigil (armodafinil) for sleep disorders. Cephalon has two additional products nearing submission.

Cephalon Will Add 250-Rep Pediatric Sales Force For Modafinil ADHD Launch

The firm plans two launches for early 2006: modafinil for attention deficit/hyperactivity disorder (formerly under the trade name Attenace) and Nuvigil (armodafinil) for sleep disorders. Cephalon has two additional products nearing submission.

Cephalon’s Nuvigil Filing Remains On Schedule For First Quarter

Cephalon's modafinil follow-on Nuvigil (armodafinil) showed statistical significance in each of four pivotal studies intended to support a first-quarter NDA filing, the firm announced Feb. 10

Related Content

Topics

UsernamePublicRestriction

Register

PS061002

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel